Abstract
Background The Covid-19 pandemic has enormously impacted the delivery of clinical healthcare and hospital management practices in most of the hospitals around the world for both Covid and no-Covid patients. In this context, it is extremely important to assess whether the clinical management of no-Covid cases has not seriously been compromised during the first epidemic outbreak. Among no-Covid cases, patients with acute myocardial infarction (AMI) and stroke need non-deferrable emergency care and are the natural candidates as no-Covid patients to be studied. Preliminary evidence suggests that i) the time from onset of symptoms to emergency department (ED) presentation has increased in Covid-19 times as well 30-day mortality during the pandemic has been higher. We aimed to complement this evidence assessing if the additional stress due to the high inflow of Covid-19 patients at hospital level has modified AMI and Stroke admission criteria and related mortality rates in a causal inference framework.
Methods To study the impact of Covid pandemic on mortality rates for AMI and Stroke we adopt two quasi-experimental approaches, regression-discontinuity design (RDD) and difference-in-regression-discontinuity (DRD) designs by which we identify the plausible causal effect on mortality of the Covid-19-related hospital stress due to the introduction of State of Emergency restrictions.
Findings We check the causal effect of the Covid-19 pandemic on mortality rates of AMI and stroke over several time-windows of 15-days around the implementation date of the State of Emergency restrictions for COVID-19 (March, 9th). Despite the potential adverse effect on expected mortality due to a longer time to hospitalization, the AMI and Stroke mortality rates are overall not statistically different from the one observed in the control group. The obtained results provided by RDD and DRD models are robust also when we account for seasonality and unobserved factors.
Interpretation In a quasi-experimental setting we assessed the causal impact of the hospital and staff extra-burden generated by the first wave of Covid-19 patients on mortality rates of no-Covid non-deferrable urgent cases (AMI and Stroke) hospitalized at Spedali Civili of Brescia, one of the most hit provinces in Italy by Covid-19 during March and May 2020. We find a non-statistically significant impact on mortality rates for AMI and Stroke patients providing evidence of the hospital ability to manage - with the implementation of a double track organization-the simultaneously delivery of high quality cares to both Covid and no-Covid patients. Availability of similar data for the regional context as a whole is needed to further substantiate the findings and explore existing differences in efficacy of different managerial settings implemented in Lombardy hospitals.
Funding All authors - except for Stefano Verzillo-acknowledge financial support from the Region of Lombardy, project 2014IT16RFOP012 ‘Misura a sostegno dello sviluppo di collaborazioni per l’identificazione di terapie e sistemi di diagnostica, protezione e analisi per contrastare l’emergenza Coronavirus e altre emergenze virali del futuro’. Stefano Verzillo has participated as external econometrician from European Commission, Joint Research Center to this project without receiving any funding or financial support, in compliance with EC rules. His contribution has been offered in the Conceptualization and Writing and Editing stages.
Role of the Funding source The founder had no roles in our study design, data collection and analysis, decision to publish and preparation of the manuscript.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authors, except for Stefano Verzillo, acknowledge financial support from the Region of Lombardy, project 2014IT16RFOP012 (Misura a sostegno dello sviluppo di collaborazioni per l identificazione di terapie e sistemi di diagnostica, protezione e analisi per contrastare l emergenza Coronavirus e altre emergenze virali del futuro). Stefano Verzillo has participated as external econometrician from European Commission, Joint Research Center to this project without receiving any funding or financial support, in compliance with EC rules. His contribution has been offered in the Conceptualization and Writing and Editing stages.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is to confirm that the study titled "The impact of COVID-19 on AMI and Stroke mortality in Lombardy: Evidence from the epicenter of the pandemic", authored by "Rossi C., Berta P., Curello S., Lovalgio P.G., Magoni M., Metra M., Roccaro A.M., Verzillo S., Vittadini G.", does not require an ethical approval. Sincerely, Sandra Sigala Brescia Ethics Committee President
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 email: camillo.rossi{at}asst-spedalicivili.it,
↵2 email: paolo.berta{at}unimib.it,
↵3 email: scurello{at}libero.it,
↵4 email: piergiorgio.lovaglio{at}unimib.it,
↵5 email: mauro.magoni{at}asst-spedalicivili.it,
↵6 email: marco.metra{at}unibs.it,
↵7 email: aldomaria.roccaro{at}asst-spedalicivili.it,
↵8 email: stefano.verzillo{at}ec.europa.eu,
↵9 email: giorgio.vittadini{at}unimib.it,
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.